ITM 2.0: Advancing Translational Science in Metropolitan Chicago

ITM 2.0：推进芝加哥大都市的转化科学

基本信息

批准号：
9779182
负责人：
Joshua J Jacobs
金额：
$ 50.53万
依托单位：
UNIVERSITY OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-06 至 2022-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9779182
关键词：
Abbreviations Academic Medical Centers Accreditation Address Advocate Aging Agreement Alzheimer&apos s Disease Attention Award Binding Bioinformatics Biotechnology Chicago Clinical Informatics Clinical Research Clinical Sciences Clinical Trials Collaborations Communities Complement Contracts Device or Instrument Development Disease Economic Policy Effectiveness Engineering Environment Epidemiology Ethics Failure Feeds Foundations Genetic Geography Glues Goals Health Health Personnel Health system Healthcare Healthcare Systems Home environment Hospitals Illinois Image Industry Institutes Institution Institutional Review Boards Intervention Investigation Lead Molecular Molecular Genetics Morbidity - disease rate Musculoskeletal Diseases Neonatology Nurses Outcome Outpatients Pediatric Hospitals Pharmaceutical Preparations Physicians Process Protocols documentation Provider Public Health Published Comment Regulatory Affairs Research Research Infrastructure Research Training Resource Sharing Resources Science Scientist Site Social Justice Standardization Technology Testing Training Translational Research Trust Universities Vision Work base clinical data warehouse clinical phenotype clinical practice community based participatory research convict data modeling data sharing design disorder risk drug discovery feeding health economics improved innovation interest metropolitan mortality multidisciplinary pre-clinical precision medicine programs social success synergism translational medicine translational pipeline

项目摘要

The University of Chicago (UChicago) Institute for Translational Medicine (ITM) was created in 2007 to assemble, integrate, and create the intellectual, administrative, and physical resources required to catalyze research and research training in Clinical and Translational Science. We have trained university scientists and health care providers to work together with stakeholders in all concerned communities to determine the molecular, genetic, pathophysiologic, and social determinants of disease; to develop and test interventions directed toward those mechanisms; and to achieve these goals in a way that is rigorous, efficient, ethical, respectful of, and responsive to our community’s needs and values. In its first 9 years, the ITM has capitalized on outstanding intellectual and physical resources throughout UChicago and at ITM affiliate institutions – Rush University Medical Center (Rush), NorthShore University HealthSystem (NorthShore), and Illinois Institute of Technology (IIT) – to build the infrastructure for a transformative, energized, and self-improving home for clinical and translational research. Now, we pursue a bold guiding vision for “ITM 2.0” – that health outcomes will be improved throughout Chicagoland by mitigating disease risk, morbidity and mortality through collaborative, multidisciplinary team science. We will work toward this vision by assembling scientific, institutional, and community stakeholders, and together focusing on the highest value propositions to improve mutually defined health concerns, leveraging synergies that accelerate progress across the translational spectrum. Our core conviction is that participating in health research is a matter of shared self-interest and social justice, a “new normal” prevailing viewpoint toward which we will strive together over the next 20 years. ITM 2.0 will work hand-in-hand with health stakeholders throughout Chicagoland and throughout the nation, conceptualizing, developing and deploying innovative processes and practices to achieve our common goal. Preparing for this ambitious challenge, we broadened the scope of institutional and community stakeholders. Rush now joins UChicago as an ITM lead institution, and Loyola University Medical Center and Advocate Health Care join as ITM affiliates. We partner with esteemed institutions – the Chicago Community Trust, the Illinois Biotechnology Industry Organization, and the Chicago and Illinois Departments of Public Health – and inclusively leverage strong collaborations with the other two Chicago CTSAs, with the Chicago-wide PCORnet CDRN CAPriCORN, and with the recently awarded Illinois Precision Medicine Consortium. In ITM 2.0, we will together develop innovative and sometimes disruptive approaches to advance the science and practice of clinical and translational research by rigorously determining which approaches work and then disseminating the results of both successes and failures. We expect that this approach will improve the conduct of and training for clinical and translational research for the benefit of Chicago, the CTSA Consortium, and the nation.

芝加哥大学 (UChicago) 转化医学研究所 (ITM) 成立于 2007 年，旨在汇集、整合和创造催化所需的智力、管理和物质资源我们培训了大学科学家和临床和转化科学方面的研究和研究培训。卫生保健提供者与所有相关社区的利益相关者合作，确定疾病的分子、遗传、病理生理和社会决定因素，以制定和测试干预措施；针对这些机制；并以严格、高效、合乎道德的方式实现这些目标；尊重并响应我们社区的需求和价值观在成立的头 9 年里，ITM 充分利用了这一优势。整个芝加哥大学和 ITM 附属机构的杰出智力和体力资源 – Rush 大学医学中心（拉什）、北岸大学医疗系统（北岸）和伊利诺伊州研究所技术 (IIT) – 为变革性的、充满活力的、自我完善的家园建设基础设施现在，我们追求“ITM 2.0”的大胆指导愿景——健康。通过降低疾病风险、发病率和死亡率，芝加哥全境的结果将得到改善我们将通过整合科学、多学科的团队科学来实现这一愿景。机构和社区利益相关者，共同关注最高价值主张，以改进共同定义的健康问题，利用协同效应加速转化进程我们的核心信念是，参与健康研究关乎共同的自身利益和利益。社会正义，这是我们未来20年共同努力的“新常态”流行观点。 ITM 2.0 将与整个芝加哥和全国的健康利益相关者携手合作，概念化、开发和部署创新流程和实践，以实现我们的共同目标。为了迎接这一雄心勃勃的挑战，我们扩大了机构和社区利益相关者的范围。 Rush 现已加入芝加哥大学作为 ITM 牵头机构，以及洛约拉大学医学中心和倡导者 Health Care 作为 ITM 附属机构加入，我们与知名机构 — 芝加哥社区信托基金会 (Chicago Community Trust) 合作。伊利诺伊州生物技术产业组织、芝加哥和伊利诺伊州公共卫生部 – 以及包容性地利用与其他两个芝加哥 CTSA 以及芝加哥范围内的 PCORnet 的强有力合作 CDRN CAPriCORN 以及最近授予的伊利诺伊州精准医学联盟在 ITM 2.0 中，我们将。共同开发创新的、有时是颠覆性的方法来推进科学和实践通过严格确定哪些方法有效然后传播来进行临床和转化研究我们期望这种方法能够改善行为和失败。为芝加哥、CTSA 联盟和国家的利益提供临床和转化研究培训。